Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets Hard-to-Treat cancers with missing gene

NCT ID NCT06810544

Disease control Sponsor: Tango Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, brain tumors, or other solid tumors that have progressed on standard treatments may join.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TNG456 (a PRMT5 inhibitor) and abemaciclib (Verzenio)
What this could lead to
If successful, this could lead to a new treatment option for certain hard-to-treat cancers that have an MTAP gene loss.
What could go wrong
This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may not work or could cause side effects.
Why investors are watching

Tango Therapeutics is testing TNG456, an oral drug for advanced solid tumors with a specific genetic marker called MTAP loss. This is the first human study of the drug, and the outcome matters because TNG456 is a key pipeline asset for a small company with few other products.

If it works: If TNG456 shows safety and signs of tumor control, Tango could advance the drug to later-stage trials and strengthen its position as a developer of targeted cancer therapies. A positive result might also attract partnership interest from larger drug companies.

If it fails: The trial could fail to show enough benefit or cause unexpected side effects, which would set the program back. Early-stage cancer trials often fail, and for a small company, a setback with a lead drug could be a major blow.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 191 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a tumor with a confirmed MTAP loss * Is ≥18 years of age at the time of signature of the main study ICF * Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate. * Is able to swallow tablets * Adequate Organ function/reserve per local labs * Negative serum pregnancy test result at screening * Has an ECOG performance status score of 0 to 1 * Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0. * Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70. Exclusion Criteria: * A female patient is who is pregnant or breastfeeding * Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s) * Has an active infection requiring systemic therapy * Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor * Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4/6 inhibitor * Clinically relevant cardiovascular disease * Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma glioma lung adenocarcinoma lung cancer lung neoplasm malignant glioma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor Glioma glioblastoma multiforme Glioma, malignant Lung cancer Non-small cell adenocarcinoma Non-small cell lung cancer Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    15 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Mayo Clinic Cancer Center

    RECRUITING

    Rochester, Minnesota, 55905-0001, United States

  • Mayo Clinic Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Scottsdale

    RECRUITING

    Scottsdale, Arizona, 85259-5452, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 11065, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Northwestern Memorial Hospital

    RECRUITING

    Chicago, Illinois, 60611-2908, United States

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Sibley Memorial Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20016, United States

  • University of California Los Angeles

    RECRUITING

    Los Angeles, California, 90995, United States

  • University of California at San Francisco

    RECRUITING

    San Francisco, California, 94143-2202, United States

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92686, United States

  • University of Utah, Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112-5500, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.